Drug intelligence / Profile preview

mifepristone + risperidone

Development stage: Unknown
Lead developer: Johnson & Johnson
Modality: Small Molecules
Administration: Oral

Overview

Mifepristone + risperidone is a combination therapy where mifepristone is used alongside risperidone to mitigate the weight gain and metabolic abnormalities commonly associated with risperidone treatment. Mifepristone is a synthetic steroid that acts as a glucocorticoid receptor antagonist, while risperidone is an atypical antipsychotic. When administered together, mifepristone has been shown to attenuate weight gain and improve metabolic parameters in patients taking risperidone, potentially improving treatment adherence and outcomes in psychiatric care.

Other names: risperidone + mifepristone

Targets

GR (Glucocorticoid receptor)PR (Progesterone receptor)AR (Adrenergic receptors)

Beyond the preview

Go deeper on mifepristone + risperidone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on mifepristone + risperidone.

Explore the full profile